Head and neck cancer, Head and neck squamous cell carcinoma, Cancer, Human papillomavirus, Solid tumor/s

Cue Biopharma, a clinical-stage biopharmaceutical company, is engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells directly within the patient's body to transform the treatment of cancer, infectious diseases and autoimmune diseases. The company's proprietary platform, Immuno-STAT ™(Selective Targeting and Alteration of T cells) is designed to harness the body's intrinsic immune system without the need for ex vivo manipulation.

Drug & Indication	Stage & Event	Catalyst Date
CUE-102 Details Wilms' Tumor 1 (WT1), Cancer	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CUE-101 (IL-2) +/- pembrolizumab Details Head and neck cancer, Head and neck squamous cell carcinoma, Cancer, Human papillomavirus, Solid tumor/s	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.

Drug Pipeline

Powered by